Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Nifedipine
Drug ID BADD_D01566
Description Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action.[A190273] The most popular of the third generation dihydropyridines is [amlodipine].[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383]
Indications and Usage Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina.[L11383] Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.[L11389,L1245]
Marketing Status approved
ATC Code C08CA05
DrugBank ID DB01115
KEGG ID D00437
MeSH ID D009543
PubChem ID 4485
TTD Drug ID D04OSE
NDC Product Code 0904-7229; 46438-0635; 52932-0711; 0069-2670; 68981-039; 23155-194; 23155-195; 43826-031; 46708-732; 50090-1843; 50742-622; 51655-738; 55289-798; 62332-734; 68084-597; 68382-687; 68645-512; 68682-106; 70771-1365; 71335-0497; 48589-0006; 51927-0233; 0069-2660; 46708-734; 50742-261; 50742-262; 51407-624; 0228-2497; 60429-049; 62175-262; 62332-732; 68084-598; 70771-1192; 71610-055; 11014-0036; 11014-0341; 52133-0028; 60592-507; 50742-260; 59651-297; 68071-2619; 68382-688; 68645-603; 68682-108; 69315-211; 70771-1191; 70807-503; 71335-0744; 71335-1721; 71335-9651; 55154-4690; 68084-603; 70934-973; 11014-0035; 11014-0342; 48292-0034; 62991-1106; 43826-030; 46708-733; 50268-598; 50742-621; 51655-780; 55154-4157; 62175-261; 63629-9109; 68382-686; 68682-105; 70771-1366; 71610-689; 0904-7081; 0069-2650; 24979-009; 24979-011; 50268-599; 50742-620; 59651-295; 59651-296; 59762-1004; 67877-757; 68645-513; 68682-109; 71205-965; 71335-0489; 71610-290; 72162-1277; 38779-0280; 51927-5205; 65427-250; 71052-650; 51655-407; 51655-798; 60429-048; 62135-521; 67877-758; 68382-689; 70934-603; 71205-963; 71335-2132; 71610-144; 72214-503; 72789-219; 49452-4847; 52133-0009; 24979-010; 50268-597; 51655-386; 62135-523; 62175-260; 62332-733; 68382-685; 71205-412; 71335-1550; 71610-012; 0904-7082; 82920-709; 43826-032; 0228-2530; 53808-1118; 62135-522; 63187-875; 68682-107; 68788-7642; 68788-8164; 69315-212; 70518-2679; 70518-3520; 12527-0787; 0904-7208; 46438-0052; 60524-002; 50090-4158; 50090-5284; 50090-5328; 50090-6201; 50090-6450; 51655-990; 55154-8177; 67877-756; 68071-4411; 68382-690; 68645-604; 70771-1190; 70771-1367; 70934-963; 71205-964; 11014-0038; 51552-0720; 50090-4234; 50090-6203; 51407-622; 51407-623; 51655-593; 60429-047
UNII I9ZF7L6G2L
Synonyms Nifedipine | Bay-1040 | Bay 1040 | Bay1040 | BAY-a-1040 | BAY a 1040 | BAYa1040 | Cordipin | Cordipine | Corinfar | Korinfar | Nifangin | Nifedipine Monohydrochloride | Monohydrochloride, Nifedipine | Procardia | Procardia XL | Nifedipine-GTIS | Nifedipine GTIS | Vascard | Adalat | Fenigidin
Chemical Information
Molecular Formula C17H18N2O6
CAS Registry Number 21829-25-4
SMILES CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pollakiuria20.02.02.007--
Polyhydramnios18.05.01.0020.000075%Not Available
Polyuria20.02.03.002--Not Available
Pre-eclampsia24.08.07.002; 20.01.08.002; 18.02.03.0020.000187%Not Available
Premature baby18.04.02.0010.001642%Not Available
Premature delivery18.07.01.0060.001022%
Premature labour18.07.01.0020.000336%Not Available
Premature rupture of membranes18.07.01.0030.000075%Not Available
Premature separation of placenta24.07.03.019; 18.02.01.0040.000187%Not Available
Proteinuria20.02.01.0110.000164%
Pruritus23.03.12.001--
Pulmonary congestion24.03.08.001; 22.01.03.002; 02.05.02.002--Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary oedema22.01.03.003; 02.05.02.0030.000485%
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.003--
Rales22.12.01.011--Not Available
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.0290.000254%Not Available
Rash macular23.03.13.003--Not Available
Rash maculo-papular23.03.13.004--
Rash pustular23.03.10.003; 11.01.12.002--
Raynaud's phenomenon24.04.03.0030.000276%Not Available
Rebound effect08.06.02.009--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Respiratory arrest22.02.01.0090.000448%Not Available
Respiratory depression17.02.05.047; 22.02.01.0100.000075%Not Available
Respiratory disorder22.02.07.002--Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000224%
Rhinitis22.07.03.006; 11.01.13.004--
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 14 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene